Paper41550465
Low Dose of IL-2 Application for Graft-Versus-Host Disease Prophylaxis Following Haploidentical Stem Cell Transplantation.
Xu ZL and 13 others. MedComm (2020), 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Low Dose of IL-2 Application for Graft-Versus-Host Disease Prophylaxis Following Haploidentical Stem Cell Transplantation. Papers, record 41550465. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41550465
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Low Dose of IL-2 Application for Graft-Versus-Host Disease Prophylaxis Following Haploidentical Stem Cell Transplantation.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22749354 | NK cell-derived interferon-γ orchestrates cellular dynamics and the differentiation of monocytes into dendritic cells at the site of infection. | Immunity | 2012 | https://conductscience.org/library/papers/22749354 | PubMed |
| 2 | 27073224 | Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. | Blood | 2016 | https://conductscience.org/library/papers/27073224 | PubMed |
| 3 | 24319201 | Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL. | Hematology Am Soc Hematol Educ Program | 2013 | https://conductscience.org/library/papers/24319201 | PubMed |
| 4 | 24686272 | Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. | Mol Ther | 2014 | https://conductscience.org/library/papers/24686272 | PubMed |
| 5 | 24719405 | Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. | Blood | 2014 | https://conductscience.org/library/papers/24719405 | PubMed |
| 6 | 18804038 | Combination therapy using IL-2 and anti-CD25 results in augmented natural killer cell-mediated antitumor responses. | Biol Blood Marrow Transplant | 2008 | https://conductscience.org/library/papers/18804038 | PubMed |
| 7 | 12480696 | CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. | Blood | 2003 | https://conductscience.org/library/papers/12480696 | PubMed |
| 8 | 20389017 | Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. | J Clin Invest | 2010 | https://conductscience.org/library/papers/20389017 | PubMed |
| 9 | 24573552 | Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/24573552 | PubMed |
| 10 | 39562716 | Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide, ATLG and non-ATLG based GvHD prophylaxis. | Bone Marrow Transplant | 2025 | https://conductscience.org/library/papers/39562716 | PubMed |
| 11 | 37968447 | Peripheral blood stem cell transplantation from haploidentical related donor could achieve satisfactory clinical outcomes for intermediate- or high-risk adult acute myeloid leukemia patients. | Bone Marrow Transplant | 2024 | https://conductscience.org/library/papers/37968447 | PubMed |
| 12 | 12925844 | CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. | Nat Med | 2003 | https://conductscience.org/library/papers/12925844 | PubMed |
| 13 | 37662885 | Mini-dose methotrexate combined with methylprednisolone as a first-line treatment for acute graft-versus-host disease: A phase 2 trial. | J Transl Int Med | 2023 | https://conductscience.org/library/papers/37662885 | PubMed |
| 14 | 38937803 | Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial. | J Hematol Oncol | 2024 | https://conductscience.org/library/papers/38937803 | PubMed |
| 15 | 38664766 | Mini-dose methotrexate combined with methylprednisolone for the initial treatment of acute GVHD: a multicentre, randomized trial. | BMC Med | 2024 | https://conductscience.org/library/papers/38664766 | PubMed |
| 16 | 25085354 | Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. | Haematologica | 2014 | https://conductscience.org/library/papers/25085354 | PubMed |
| 17 | 28104702 | IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. | Haematologica | 2017 | https://conductscience.org/library/papers/28104702 | PubMed |
| 18 | 37827864 | IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy. | Trends Immunol | 2023 | https://conductscience.org/library/papers/37827864 | PubMed |
| 19 | 37363859 | Antibody-mediated pathogenesis of chronic GVHD through DBY/HLA class II complexes and induction of a GVL effect. | Blood | 2023 | https://conductscience.org/library/papers/37363859 | PubMed |
| 20 | 11896281 | Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. | Science | 2002 | https://conductscience.org/library/papers/11896281 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41550465 | Low Dose of IL-2 Application for Graft-Versus-Host Disease Prophylaxis Following Haploidentical Stem Cell Transplantation. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/41550465 |
Source PubMed
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD226 | 10666 | PubTator's text mining | https://conductscience.org/library/genes/10666 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| IL10 | 3586 | PubTator's text mining | https://conductscience.org/library/genes/3586 | NCBI Gene |
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 | NCBI Gene |
| IL2RB | 3560 | PubTator's text mining | https://conductscience.org/library/genes/3560 | NCBI Gene |
| KLRC1 | 3821 | PubTator's text mining | https://conductscience.org/library/genes/3821 | NCBI Gene |
| KLRK1 | 22914 | PubTator's text mining | https://conductscience.org/library/genes/22914 | NCBI Gene |
| SELL | 6402 | PubTator's text mining | https://conductscience.org/library/genes/6402 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41550465
GET https://conductscience.org/api/papers/v1/41550465/references?page=2